Genomic drug sensitivity biomarker for TTK inhibitors published in Molecular Cancer Therapeutics
In a new publication, NTRC scientists propose mutations in the cancer hot spot region of the β-catenin gene (CTNNB1) as prognostic drug sensitivity biomarkers for TTK inhibitors.
Read more
New at Pivot Park – Atro Medical
ATRO Medical is focusing their R&D activities on the meniscus prothesis Trammpolin™.
Read more
NTRC expands Oncolines™ cell line panel to 102 cell lines
NTRC has launched an expansion of its Oncolines™ cancer cell line panel, from 66 to 102 cell lines.
Read more
Successful first-in-human study exploiting a unique scalable Natural Killer-cell product
We report the first-in-human study exploiting a unique scalable NK-cell product generated ex vivo from CD34+ hematopoietic stem and progenitor cells (HSPC) from partially HLA-matched umbilical cord blood units.
Read more
PimBio vestigt zich op Pivot Park
Per 1 juni zijn de deuren van het kantoor van PimBio op Pivot Park geopend.
Read more
NTRC publishes target residence time-guided optimization of TTK inhibitors
This week, NTRC published results from its TTK (Mps1) drug discovery programme in the Journal of Molecular Biology.
Read more
Pluriomics BV partners with Pivot Park Screening Centre
Pluriomics partners with Pivot Park Screening Centre for Cardiovascular drug discovery services.
Read more
Synaffix Secures End-to-End Patent Protection of Its ADC Technology Platform as Its HydraSpace™ Patent Grants in the United States
Synaffix announced that a key patent covering its HydraSpace™ spacer technology has been granted by the US Patent and Trademark Office.
Read more
Lead Pharma Achieves Second Milestone for Development of Autoimmune Diseases Treatments in Sanofi Collaboration
Lead Pharma announced that it has achieved a second milestone under its research collaboration with Sanofi.
Read more